Author

B. Wright

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:statistical model· 3 Research Focus:differential expression· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:ecology & biodiversity· 1 Organism:mouse· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

H. Lockstone· 2 shared A. Biroccio· 1 shared A. C. Algar· 1 shared A. Doroff· 1 shared A. Harris· 1 shared A. Londono· 1 shared A. Miar· 1 shared C. C. Roggatz· 1 shared

Activity by Year

2018-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

H. Lockstone

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Ly6Chi monocytes are metabolically reprogrammed in the blood during inflammatory stimulation allowing for macrophage lineage commitment

G. Purvis, E. McNeill, B. Wright, S. Revale, H. Lockstone, K. Channon, D. Greaves

The paper shows Ly6Chi monocytes undergo metabolic reprogramming during inflammation, enabling macrophage lineage commitment through oxidative phosphorylation.

bioRxiv · Nov 15, 2021 · PreprintImmunology

Saxitoxin and tetrodotoxin bioavailability increases in future oceans

C. C. Roggatz, N. Fletcher, D. M. Benoit, A. C. Algar, A. Doroff, B. Wright, K. C. Wollenberg Valero, J. D. Hardege

This study shows that rising ocean temperatures and declining pH increase the bioavailability of saxitoxin and tetrodotoxin, enhancing toxicity and ecological impacts.

bioRxiv · Mar 6, 2019Pharmacology & Toxicology

BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors

T. Reislander, E. Puig Lombardi, F. J. Groelly, A. Miar, M. Porru, B. Wright, H. Lockstone, A. Biroccio, A. Harris, A. Londono, M. Tarsounas

This study shows that BRCA2 loss in cancer cells triggers innate immune responses, which are enhanced by PARP inhibitors, suggesting a mechanism for their therapeutic effect.

bioRxiv · Dec 10, 2018Cancer Biology